Skip to main content
RARE logo

Ultragenyx Pharmaceutical Inc.

RARENASDAQHealthcareBiotechnology

$15.17Today:- (-)1Y −55.34%

As of Oct 15, 2026 close

Market cap
$1.55B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$12.73$39.89
Volume (live)
-
Avg. volume (3M)
6.14M

Ultragenyx Pharmaceutical Inc. (RARE) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Ultragenyx Pharmaceutical Inc. stock.

Analyst Consensus Rating

Investment consensus from 23 professional research analysts

Consensus Rating

Hold
Based on 23 unique analysts
(25 total ratings in last 90 days)
Very High Confidence∞:1 Buy/Sell

Average Price Target

$28.47
+87.67% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest RARE Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Tazeen Ahmad
BofA Securities
HoldMaintains
$20.00
Luca Issi
RBC Capital
HoldMaintains
$19.00
Ram Selvaraju
HC Wainwright
BuyReiterates
$25.00
Zacks Equity Research
Zacks Equity Research
HoldInitiates Coverage
-
Ram Selvaraju
HC Wainwright
BuyReiterates
$25.00
Gavin Clark-Gartner
Evercore ISI Group
HoldMaintains
$16.00 → $18.00
Maxwell Skor
Morgan Stanley
HoldReiterates
$18.00 → $20.00
Whitney Ijem
Canaccord Genuity
BuyReiterates
$37.00 → $39.00
Laura Chico
Wedbush
HoldMaintains
$23.00
Kristen Kluska
Cantor Fitzgerald
BuyMaintains
$33.00 → $39.00
Sami Corwin
William Blair
HoldMaintains
-
Joseph Schwartz
Leerink Partners
BuyMaintains
$33.00
Eliana Merle
Barclays
BuyMaintains
$32.00 → $35.00
Yigal Nochomovitz
Citi
BuyMaintains
$31.00 → $32.00
Benjamin Burnett
Wells Fargo
HoldReiterates
$18.00
Kristen Kluska
Cantor Fitzgerald
BuyMaintains
$33.00 → $39.00
Salveen Richter
Goldman Sachs
HoldMaintains
$28.00 → $19.00
Edmund Ingham
Forbes
HoldInitiates Coverage
-
Maury Raycroft
Jefferies
BuyMaintains
$77.00 → $28.00
Yaron Werber
TD Cowen
BuyInitiates Coverage
$49.00 → $18.00
Anupam Rama
JP Morgan
HoldUpgrades
$80.00 → $36.00
Jack Allen
Baird
HoldUpgrades
$40.00 → $16.00
Ahan Chakraborty
Zacks Equity Research
HoldInitiates Coverage
-
Allison Bratzel
Piper Sandler
BuyMaintains
$68.00
Debjit Chattopadhyay
Guggenheim
BuyMaintains
$43.00 → $35.00

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 9, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for RARE?

The analyst consensus rating for RARE is Hold, based on the latest ratings from 23 analysts over the last 90 days.

What is the average price target for RARE?

The average 12-month price target for RARE is $28.47, representing an upside of 87.7% from the Oct 15, 2026 close of $15.17.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.